AMRN Amarin Corporation plc
USHealthcareAs of 2026-07-08 16:00
Why AMRN matters now
Amarin Corporation plc (AMRN) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.17 with -1.88% on the session and $313.8M in market capitalization; recent performance reads 1-month +14.09% and YTD +14.83%.
The latest financial table shown here is Q1 2026, with revenue of $43.3M, net income of $-10.5M, and EPS of $-0.51. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 7.7%.
The latest indexable market news headline is "Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Sell with a median target of $2.00; recent insider activity includes Bonfiglio Patrice Eadon filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.74
P/S
1.54
EV/EBITDA
-40.09
DCF Value
$-19.97
FCF Yield
7.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.5%
Operating Margin
-17.4%
Net Margin
-15.6%
ROE
-7.3%
ROA
-5.2%
ROIC
-7.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $43.3M | $-10.5M | $-0.51 |
| Q4 2025 | $49.1M | $-1.2M | $-0.06 |
| FY 2025 | $213.6M | $-38.8M | $-1.80 |
| Q3 2025 | $49.7M | $-7.7M | $-0.37 |
Analyst Ratings
Consensus
Sell
Target (Consensus)
$2.17
Target (Median)
$2.00
Target Range
$1.50 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IE
Exchange
—
Beta
0.82
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.